Last reviewed · How we verify

Mosunetuzumab (SC) — Competitive Intelligence Brief

Mosunetuzumab (SC) (Mosunetuzumab (SC)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody (T-cell engager). Area: Oncology.

phase 3 Bispecific antibody (T-cell engager) CD20 and CD3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Mosunetuzumab (SC) (Mosunetuzumab (SC)) — The Lymphoma Academic Research Organisation. Mosunetuzumab is a bispecific antibody that simultaneously engages CD20 on B cells and CD3 on T cells to redirect T cell killing of B cell lymphomas.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mosunetuzumab (SC) TARGET Mosunetuzumab (SC) The Lymphoma Academic Research Organisation phase 3 Bispecific antibody (T-cell engager) CD20 and CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody (T-cell engager) class)

  1. The Lymphoma Academic Research Organisation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mosunetuzumab (SC) — Competitive Intelligence Brief. https://druglandscape.com/ci/mosunetuzumab-sc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: